Showing 201-210 of 4877 results for "".
- Burt's Bees Sensitive Skincare Line Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/burts-bees-sensitive-skincare-line-awarded-national-eczema-association-seal-of-acceptance/2457892/The National Eczema Society (NEA) has awarded Burt's Bees' Sensitive skin care line the NEA's Seal of Acceptance, which maintains rigorous standards for approval. The Sensitive skin care line includes Burt's Bees Sensitive Facial Cleanser, Burt's Bees Sensitive Eye Cream, Burt
- Botox Hits the Big 3-0https://practicaldermatology.com/news/botox-hits-the-big-3-0/2460184/Botox is turning 30, and Allergan fêted its shining star, Botox Cosmetic, in style at a New York City bash. The event included the debut of Botox Cosmetic’s new packaging and a panel discussion featuring New York City dermatologists Macrene Alexiades-Armenakas, MD, PhD
- Potential Notalgia Paresthetica Breakthrough: Oral Difelikefalin May Curb Persistent Itchhttps://practicaldermatology.com/news/potential-notalgia-paresthetica-breakthrough-oral-difelikefalin-may-curb-persistent-itch/2461553/Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no U.S. Food and Drug Administration (FDA)-approved treatments specifically targeting this disorder. But a new s
- Almirall and University of Michigan Collaborate to Gain Understanding of Disease Drivers in Hidradenitis Suppurativahttps://practicaldermatology.com/news/almirall-and-university-of-michigan-collaborate-to-gain-understanding-of-disease-drivers-in-hidradenitis-suppurativa/2461107/Almirall, S.A. entered into a collaboration agreement with the University of Michigan to accelerate the understanding of the factors that trigger hidradenitis suppurativa. Through this partnership, Almirall's expertise in skin diseases will be combined with the knowledge of the Dermatolo
- FDA: Pills Don't Replace Sunscreenhttps://practicaldermatology.com/news/fda-pills-dont-replace-sunscreen/2457749/The U.S. Food and Drug Administration (FDA) is cracking down on companies marketing supplements that claim to counter the effects of the sun's ultraviolet rays. These companies — marketing products called
- Houston Dermatologist Rolls Out New Class of Topical Pain Relievershttps://practicaldermatology.com/news/houston-dermatologist-rolls-out-new-class-of-topical-pain-relievers/2461974/Milton D. Moore, MD, a dermatologist and founder & CEO of Moore Unique Skin Care, LLC and
- Drs. Neal Bhatia and Ted Rosen Present New Therapeutics ‘Popping’ in 2026https://practicaldermatology.com/news/drs-neal-bhatia-and-ted-rosen-present-new-therapeutics-popping-in-2026/2485511/In their annual overview of therapeutics at Maui Derm Hawaii 2026, Ted Rosen, MD, and Neal Bhatia, MD, used a K-Pop Demon Hunters theme to walk through emerging strategies across inflammatory skin diseases. Drs. Rosen and Bhatia emphasized a shift toward non‑steroidal topicals that can be
- Skin Cancer Champions Launches Integrated Public, Private Communityhttps://practicaldermatology.com/news/skin-cancer-champions-launches-integrated-public-private-community/2484106/The Skin Cancer Champions organization, led by dermatologists Emily Ruiz, MD, MPH, and Chrysalyne Schmults, MD, MSce, FAAD, announced the official launch of its integrated public and private community at skincancerchampions.org. The public platform expands the group’s reach by offering edu
- CHE Talk at Fall Clinical Highlights Precision Therapieshttps://practicaldermatology.com/news/che-talk-at-fall-clinical-highlights-precision-therapies/2484094/With new FDA approvals, investigational therapies nearing the finish line, and a greater understanding of disease heterogeneity, chronic hand eczema (CHE) is increasingly viewed as a condition requiring individualized, mechanistically informed care, Alexandra Golant, MD, and Benjamin Ehst, MD, Ph
- Emerging Treatments for CLE Highlighted at Fall Clinicalhttps://practicaldermatology.com/news/emerging-treatments-for-cle-highlighted-at-fall-clinical/2484091/Cutaneous lupus erythematosus (CLE) patients often face long treatment timelines, drug toxicity, and misdiagnoses, but recent advances in mechanism-based agents mark a significant step forward, Lauren Graham, MD, PhD, and Alisa Femia, MD, said during a presentation at the 2025 Fall Clinical Derma